Immune Related Adverse Events
Checkpoint inhibitor response, adverse event rate similar regardless of autoimmune disease
Patients’ response to anti-CTLA-4 or anti-PD-1 checkpoint therapy for advanced melanoma, and their incidence of immune-related adverse events of grade 3 or higher, were similar regardless of preexisting autoimmune disease, according to data.
Accurately attributing toxicity with combination regimens: An emerging practice challenge
The use of immune checkpoint inhibitors in cancer care has expanded exponentially over the last few years.
Targeting immune checkpoints holds 'promise of more potent, refined' autoimmune therapies
Targeting immune checkpoints remains a key strategy in the development of treatments aimed at autoimmune disease and cancer, as well as for improving transplant outcomes, according to a review published in the Journal of Autoimmunity.
Walking the tightrope: Balancing tumor response, adverse events of checkpoint inhibitors
Time moves in funny ways in medicine. Physicians and researchers can work for decades in obscurity on a cure for a particular disease and make little progress. But once the critical breakthrough comes, 6 months or a year can change everything.